HOOKIPA to Participate in the Sidoti Micro-Cap Virtual Conference

Rhea-AI Summary

HOOKIPA Pharma Inc. (NASDAQ: HOOK) will participate in the Sidoti Micro-Cap Virtual Conference on November 9-10, 2022. The company's corporate presentation is scheduled for November 10 at 12:15 PM EST. The event will be accessible through a webcast on HOOKIPA's website, with an archived replay available for 30 days post-event.

HOOKIPA focuses on developing innovative immunotherapeutics using its proprietary arenavirus platform to combat serious diseases like Human Papillomavirus 16-positive cancers and prostate cancers, with collaborations with Roche and Gilead.

NEW YORK and VIENNA, Austria, Nov. 02, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the company will participate in the Sidoti Micro-Cap Virtual Conference, November 9 - 10, 2022.

Corporate Presentation: Thursday, November 10, 2022 at 12:15 PM EST

The webcast of the presentation will be available within the Investors & Media section of HOOKIPA’s website at https://ir.hookipapharma.com/events. An archived replay will be accessible for 30 days following the event.

About HOOKIPA

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. HOOKIPA’s pipeline includes its wholly owned investigational arenaviral immunotherapies targeting Human Papillomavirus 16-positive cancers, prostate cancers, and other undisclosed programs. HOOKIPA is collaborating with Roche on an arenaviral immunotherapeutic for KRAS-mutated cancers. In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.

Find out more about HOOKIPA online at www.hookipapharma.com.

For further information, please contact:

Media	Investors
Instinctif Partners	Matt Beck
hookipa@instinctif.com	Executive Director - Investor Relations
+44 (0)20 7457 2020	matthew.beck@hookipapharma.com
	+1 917 209 6886

FAQ

When is HOOKIPA Pharma's corporate presentation at the Sidoti Micro-Cap Virtual Conference?

HOOKIPA Pharma's corporate presentation is scheduled for November 10, 2022, at 12:15 PM EST.

How can I access the webcast of HOOKIPA's presentation?

The webcast of HOOKIPA's presentation will be available in the Investors & Media section of their website.

What is HOOKIPA Pharma's focus in biopharmaceuticals?

HOOKIPA Pharma focuses on developing novel immunotherapies based on its proprietary arenavirus platform.

What diseases is HOOKIPA targeting with its therapies?

HOOKIPA is targeting Human Papillomavirus 16-positive cancers and prostate cancers, among other diseases.

Is HOOKIPA collaborating with other companies?

Yes, HOOKIPA is collaborating with Roche on an immunotherapeutic for KRAS-mutated cancers and with Gilead for HBV and HIV.